title: Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years.
abstract: OBJECTIVE
  It has been reported that aspirin and other non-steroidal anti-inflammatory drugs (NSAID) may protect against dementia of Alzheimer's type and/or vascular dementia. However, co-morbidity and the dose of aspirin may be critical. A major indication for low-dose aspirin is prophylaxis after stroke and transient ischaemic attacks, conditions that may obscure an anti-dementia effect by the drug. Alternatively, low-dose aspirin may be insufficient if the protective effect is due to an anti-inflammatory mechanism. The aim of this study was to assess whether high-dose or low-dose aspirin may protect against Alzheimer's dementia in subjects aged > or =80 years. For comparison, effects of (other) NSAID, paracetamol and D-propoxyphene were studied.
  
  
  METHODS
  Global, cross-sectional, and longitudinal (1991-2000) epidemiological analyses of clinical, cognitive and drug treatment data on 702 individuals 80 years old or more (351 twin pairs of same sex), all alive at inclusion: mean age 83.9 years (80-99 years). Calculations were made with logistic regression of associations between use of various analgesics and cognitive function, after adjustment for age, gender, and cardiovascular and cerebrovascular diseases.
  
  
  RESULTS
  Users of high-dose aspirin had significantly lower prevalence of Alzheimer's dementia and better-maintained cognitive function than non-users. There were numerically similar but not significant associations with use of low-dose aspirin and other NSAID. There were no such associations with use of either paracetamol or D-propoxyphene.
  
  
  CONCLUSIONS
  Aspirin might protect against Alzheimer's disease, but controlled trials are warranted.
authors.affiliation: Institute of Gerontology, School of Health Sciences, Jönköping University, Jönköping, Sweden.
authors.forename: Sven E
authors.initials: SE
authors.lastname: Nilsson
authors.forename: Boo
authors.initials: B
authors.lastname: Johansson
authors.forename: Sanna
authors.initials: S
authors.lastname: Takkinen
authors.forename: Stig
authors.initials: S
authors.lastname: Berg
authors.forename: Steven
authors.initials: S
authors.lastname: Zarit
authors.forename: Gerald
authors.initials: G
authors.lastname: McClearn
authors.forename: Arne
authors.initials: A
authors.lastname: Melander
mesh_terms: D000082:Acetaminophen / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000517:prevention & control*; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D003430:Cross-Sectional Studies; D011431:Dextropropoxyphene / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009483:Neuropsychological Tests; D013548:Sweden; D014427:Twins
chemical_list: D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000082:Acetaminophen; D001241:Aspirin; D011431:Dextropropoxyphene